Equities Analysts Offer Predictions for ACAD FY2025 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the biopharmaceutical company will post earnings of $0.24 per share for the year. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.06. The company had revenue of $250.40 million during the quarter, compared to the consensus estimate of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. ACADIA Pharmaceuticals’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.40) earnings per share.

Other equities analysts also recently issued reports about the stock. StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Raymond James reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.25.

ACADIA Pharmaceuticals Trading Down 2.1 %

ACAD opened at $18.67 on Thursday. The firm has a market cap of $3.11 billion, a price-to-earnings ratio of 23.94 and a beta of 0.37. ACADIA Pharmaceuticals has a 12 month low of $14.15 and a 12 month high of $27.94. The stock has a fifty day moving average price of $17.29 and a 200-day moving average price of $16.61.

Insider Activity at ACADIA Pharmaceuticals

In other news, COO Brendan Teehan sold 10,329 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $173,630.49. Following the transaction, the chief operating officer now owns 62,105 shares in the company, valued at $1,043,985.05. This trade represents a 14.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider James Kihara sold 4,073 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $68,467.13. Following the completion of the sale, the insider now directly owns 19,863 shares of the company’s stock, valued at approximately $333,897.03. The trade was a 17.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,661 shares of company stock worth $414,551 in the last three months. Company insiders own 28.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC lifted its position in shares of ACADIA Pharmaceuticals by 5.6% in the second quarter. Commonwealth Equity Services LLC now owns 14,770 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 778 shares in the last quarter. American Century Companies Inc. lifted its holdings in ACADIA Pharmaceuticals by 76.7% in the 2nd quarter. American Century Companies Inc. now owns 73,148 shares of the biopharmaceutical company’s stock valued at $1,189,000 after purchasing an additional 31,762 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in ACADIA Pharmaceuticals by 1.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 107,543 shares of the biopharmaceutical company’s stock valued at $1,748,000 after purchasing an additional 1,964 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of ACADIA Pharmaceuticals during the second quarter worth $10,550,000. Finally, Bank of Montreal Can acquired a new stake in shares of ACADIA Pharmaceuticals in the second quarter valued at about $1,570,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.